NCT00140907View on ClinicalTrials.gov

ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)

PHASE4CompletedINTERVENTIONAL
Enrollment

367

Participants

Timeline

Start Date

March 14, 2000

Primary Completion Date

January 1, 2005

Study Completion Date

January 1, 2005

Conditions
High Blood Pressure
Interventions
DRUG

losartan potassium

25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.

DRUG

Comparator: Placebo

25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00140907 - ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED) | Biotech Hunter | Biotech Hunter